Financhill
Buy
64

SOPH Quote, Financials, Valuation and Earnings

Last price:
$5.07
Seasonality move :
-18.34%
Day range:
$4.92 - $5.24
52-week range:
$2.58 - $5.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.39x
P/B ratio:
7.63x
Volume:
83.4K
Avg. volume:
104.1K
1-year change:
53.19%
Market cap:
$359.8M
Revenue:
$77.3M
EPS (TTM):
-$1.17

Analysts' Opinion

  • Consensus Rating
    SOPHiA GENETICS SA has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $7.67, SOPHiA GENETICS SA has an estimated upside of 52.12% from its current price of $5.04.
  • Price Target Downside
    According to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $5.04.

Fair Value

  • According to the consensus of 4 analysts, SOPHiA GENETICS SA has 52.12% upside to fair value with a price target of $7.67 per share.

SOPH vs. S&P 500

  • Over the past 5 trading days, SOPHiA GENETICS SA has overperformed the S&P 500 by 3.09% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • SOPHiA GENETICS SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • SOPHiA GENETICS SA has grown year-over-year revenues for 5 quarters straight. In the most recent quarter SOPHiA GENETICS SA reported revenues of $21.7M.

Earnings Growth

  • SOPHiA GENETICS SA earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter SOPHiA GENETICS SA reported earnings per share of -$0.28.
Enterprise value:
353.9M
EV / Invested capital:
--
Price / LTM sales:
4.39x
EV / EBIT:
--
EV / Revenue:
4.58x
PEG ratio (5yr expected):
-0.18x
EV / Free cash flow:
-7.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$52.1M
Return On Assets:
-48.91%
Net Income Margin (TTM):
-102.24%
Return On Equity:
-107.74%
Return On Invested Capital:
-64.02%
Operating Margin:
-83.15%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Income Statement
Revenue $62.4M $65.2M $77.3M $17.7M $21.7M
Gross Profit $42.9M $43.9M $52.1M $12.1M $14.7M
Operating Income -$75.8M -$66.8M -$69.9M -$17.6M -$18M
EBITDA -$67.4M -$58.2M -$60.4M -$15.3M -$15.6M
Diluted EPS -$1.22 -$0.95 -$1.17 -$0.23 -$0.28
Period Ending 2021-12-31 2022-12-31 2023-12-31 2024-12-31 2025-12-31
Balance Sheet
Current Assets $282.7M $196.3M $148M $99.4M $99.1M
Total Assets $320.2M $243.8M $206.2M $156.4M $163.5M
Current Liabilities $28.6M $26.8M $35.6M $26.8M $50.5M
Total Liabilities $44.8M $43.7M $54.7M $59.9M $116.3M
Total Equity $275.4M $200.1M $151.4M $96.5M $47.1M
Total Debt $13.1M $16.7M $18.6M $30M $63M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Cash Flow Statement
Cash Flow Operations -$49.2M -$42.9M -$39.5M -$10.2M -$8.9M
Cash From Investing $8.4M -$8.2M -$10.9M -$1.9M -$3.9M
Cash From Financing -$2.9M $11.6M $35.5M -$744.7K $397K
Free Cash Flow -$58.5M -$51.1M -$48.5M -$12.1M -$11.4M
SOPH
Sector
Market Cap
$359.8M
$23.9M
Price % of 52-Week High
88.42%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-2.43%
-1.9%
1-Year Price Total Return
53.19%
-18.29%
Beta (5-Year)
--
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $4.86
200-day SMA
Buy
Level $4.22
Bollinger Bands (100)
Buy
Level 4.45 - 5.11
Chaikin Money Flow
Sell
Level -469.7K
20-day SMA
Buy
Level $4.79
Relative Strength Index (RSI14)
Buy
Level 57.94
ADX Line
Buy
Level 15.3
Williams %R
Neutral
Level -38.75
50-day SMA
Buy
Level $4.82
MACD (12, 26)
Buy
Level 0.07
25-day Aroon Oscillator
Buy
Level 52
On Balance Volume
Neutral
Level 12.2M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-3.4005)
Sell
CA Score (Annual)
Level (-2.5089)
Buy
Beneish M-Score (Annual)
Level (-3.1269)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (4.4267)
Buy
Piotroski F Score (Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Stock Forecast FAQ

In the current month, SOPH has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SOPH average analyst price target in the past 3 months is $7.67.

  • Where Will SOPHiA GENETICS SA Stock Be In 1 Year?

    According to analysts, the consensus estimate is that SOPHiA GENETICS SA share price will rise to $7.67 per share over the next 12 months.

  • What Do Analysts Say About SOPHiA GENETICS SA?

    Analysts are divided on their view about SOPHiA GENETICS SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SOPHiA GENETICS SA is a Sell and believe this share price will drop from its current level to $7.00.

  • What Is SOPHiA GENETICS SA's Price Target?

    The price target for SOPHiA GENETICS SA over the next 1-year time period is forecast to be $7.67 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SOPH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for SOPHiA GENETICS SA is a Buy. 4 of 4 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of SOPH?

    You can purchase shares of SOPHiA GENETICS SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SOPHiA GENETICS SA shares.

  • What Is The SOPHiA GENETICS SA Share Price Today?

    SOPHiA GENETICS SA was last trading at $5.07 per share. This represents the most recent stock quote for SOPHiA GENETICS SA. Yesterday, SOPHiA GENETICS SA closed at $5.04 per share.

  • How To Buy SOPHiA GENETICS SA Stock Online?

    In order to purchase SOPHiA GENETICS SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Celestica The Best AI Stock to Buy Now?
Is Celestica The Best AI Stock to Buy Now?

Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…

Will AI Disrupt SaaS Software Stocks?
Will AI Disrupt SaaS Software Stocks?

Since January 28th, software stocks in the United States have…

Why Is Meta Stock Going Higher?
Why Is Meta Stock Going Higher?

Over the last five days, shares of Instagram and Facebook…

Stock Ideas

Sell
46
Is NVDA Stock a Buy?

Market Cap: $4.3T
P/E Ratio: 36x

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 34x

Sell
40
Is GOOGL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 27x

Alerts

Buy
51
AAOI alert for Apr 4

Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.

Buy
59
SBAC alert for Apr 4

SBA Communications Corp. [SBAC] is up 18.96% over the past day.

Buy
55
VSAT alert for Apr 4

ViaSat, Inc. [VSAT] is up 18.73% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock